Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1973 1
1974 2
1975 1
1977 1
1978 1
1979 3
1980 3
1981 1
1982 3
1983 3
1984 4
1985 3
1986 4
1987 3
1988 3
1989 4
1990 7
1991 3
1992 4
1993 8
1994 5
1995 7
1996 7
1997 8
1998 4
1999 3
2000 6
2001 4
2002 2
2003 6
2004 4
2005 9
2006 11
2007 4
2008 4
2009 4
2010 8
2011 9
2012 6
2013 4
2014 7
2015 8
2016 13
2017 4
2018 8
2019 6
2020 9
2021 8
2022 9
2023 10
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

246 results

Results by year

Filters applied: . Clear all
Page 1
[Samples in Coagulation Test].
Komiyama Y. Komiyama Y. Rinsho Byori. 2015 Dec;63(12):1397-404. Rinsho Byori. 2015. PMID: 27089656 Review. Japanese.
Natural Transformation in Escherichia coli.
Komiyama Y, Maeda S. Komiyama Y, et al. Methods Mol Biol. 2020;2075:179-187. doi: 10.1007/978-1-4939-9877-7_13. Methods Mol Biol. 2020. PMID: 31584163
Oral lesions preceding paediatric perianal fistulising Crohn's disease.
Fujita Y, Tominaga K, Tanaka T, Komiyama Y, Ihara K, Ishida K, Yoshihara S. Fujita Y, et al. Among authors: komiyama y. J Paediatr Child Health. 2022 Dec;58(12):2336-2337. doi: 10.1111/jpc.16260. Epub 2022 Oct 21. J Paediatr Child Health. 2022. PMID: 36269610 No abstract available.
Effect of a combination of pemafibrate and a mild low-carbohydrate diet on obese and non-obese patients with metabolic-associated fatty liver disease.
Suzuki Y, Maekawa S, Yamashita K, Osawa L, Komiyama Y, Nakakuki N, Takada H, Muraoka M, Sato M, Takano S, Fukasawa M, Yamaguchi T, Funayama S, Morisaka H, Onishi H, Enomoto N. Suzuki Y, et al. Among authors: komiyama y. J Gastroenterol Hepatol. 2023 Jun;38(6):921-929. doi: 10.1111/jgh.16154. Epub 2023 Mar 5. J Gastroenterol Hepatol. 2023. PMID: 36811251
Impact of Renal Function on the Prognosis of Patients Receiving Atezolizumab/Bevacizumab Combination Therapy and Lenvatinib Monotherapy for Unresectable Hepatocellular Carcinoma.
Takada H, Yamashita K, Osawa L, Komiyama Y, Nakakuki N, Muraoka M, Suzuki Y, Sato M, Takano S, Fukasawa M, Yamaguchi T, Maekawa S, Takahashi K, Uchimura K, Enomoto N. Takada H, et al. Among authors: komiyama y. Oncology. 2023;101(10):609-623. doi: 10.1159/000531111. Epub 2023 Jun 6. Oncology. 2023. PMID: 37279708
Significance of the autoantibody assay in predicting the development of immune-related adverse events in patients receiving atezolizumab plus bevacizumab combination therapy for unresectable hepatocellular carcinoma.
Takada H, Yamashita K, Osawa L, Komiyama Y, Muraoka M, Suzuki Y, Sato M, Kobayashi S, Yoshida T, Takano S, Maekawa S, Enomoto N. Takada H, et al. Among authors: komiyama y. Hepatol Res. 2024 Feb;54(2):162-173. doi: 10.1111/hepr.13969. Epub 2023 Oct 6. Hepatol Res. 2024. PMID: 37740643
246 results